2.2 Diffuse large B-cell lymphoma (DLBCL) and CRISPR Cas9
Diffuse large B-cell lymphoma is the most common non-Hodgkin’s lymphoma and has a high heterogeneity, accounting for approximately 1/3 of all cases 29. The standard first-line treatment regimen today is rituximab (R) + CHOP (cyclophosphamide + adriamycin + vincristine + prednisone), with 5-year survival rates of 60%-70% for patients taking first-line chemotherapy30, but more than 30% of patients will still develop relapsed/refractory DLBCL due to resistance to targeted and chemotherapeutic agents, resulting in poor prognosis29,30.